News for Dr. Reddy's Laboratories Limited (RDY)

SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's') for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and regions and the United States (U.S.).

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased revenue. See why RDY stock is a Buy.

The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2025 Q3 earnings call.

Jan 23, 2025 / 02:00PM GMTOperator Ladies and gentlemen, good day, and welcome to the Quarter 3 FY25 Earnings Conference Call of Dr. Reddy's Laboratories Limite

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ETCompany ParticipantsRicha Periwal – Head-Investor...

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therape

Earnings call: Dr. Reddy's reports robust growth and strategic expansions

Nov 05, 2024 / 02:00PM GMTOperator Ladies and gentlemen, good day and welcome to the quarter two FY25 earnings conference call of Dr. Reddy's Laboratories Limit

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ETCompany ParticipantsRicha Periwal - Head of Investor...

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia ® and Xgeva ®

Amphastar Pharmaceuticals has seen significant growth since its IPO, with its stock price increasing over 500%. Learn more about AMPH stock here.

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia ® & Xgeva ® in the U.S., Europe and UK

Dr. Reddy's Laboratories Limited (NYSE:NYSE:RDY) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ETCompany ParticipantsRicha Periwal - Head of...

DeepMatter to trial its DigitalGlassware® platform with Aurigene Pharmaceutical Services DeepMatter Group Plc , the international digital chemistry... | October 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju...

DUBAI, UAE, June 3, 2021 /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its